Reme-D key facts
as of Oct 2026- Provider of molecular diagnostic kits intended to enhance the accuracy and timeliness of disease detection.
- Reme-D is valued at approximately $330K as of Oct 2026 (last reported valuation).
- It has raised $520K; the latest was Early Stage VC ($500K) in Apr 2026.
- Notable investors include Techstars, Mohammed Bin Rashid Innovation Fund, African Union Development Agency-NEPAD, A15, Global Innovation Fund — 8 tracked in total.
- Status: Privately Held (backing).
Reme-D's last reported valuation, May 2024. Nothing priced has surfaced since.
- ·Watch Reme-D: the Monday email on marks, rounds and moves
Reme-D funding rounds
No funding rounds for Reme-D are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Reme-D valuation
Reme-D's last reported valuation was $330,000 in May 2024. No priced round, secondary trade or fund mark has surfaced since.
Reme-D investors
8 investors are on record for Reme-D, including Techstars, Mohammed Bin Rashid Innovation Fund, African Union Development Agency-NEPAD and A15.
About Reme-D
Provider of molecular diagnostic kits intended to enhance the accuracy and timeliness of disease detection. The company's technology facilitates precise and efficient nucleic acid extraction and advanced techniques for amplification and detection, incorporating features such as shorter and simpler testing protocols with increased stability in hot and humid climates, enabling global populations in underserved areas to access accurate and reliable diagnostics and treatment information.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 32
- Website
- reme-d-inc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.